Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities.

J Hematol Oncol · 2023 · PMC10725587 · PMID 38104104

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend is also highlighted in a Phase II clinical trial ( NCT03091478 ) testing pembrolizumab for multiple solid tumors, including NSCLC, head/neck or skin squamous carcinoma, breast cancer and glioma [ 142 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.